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SUMMARY
A total of 220 patients with arthropathy were selected in Belém, Pará between January 1994 and December 2000, and screened
for the presence of human parvovirus B19 IgM and IgG antibodies by enzyme-linked immunosorbent assay (ELISA). A subgroup (n
= 132) of patients with high levels of antibodies (either IgM+/IgG+ or IgM-/IgG+) were examined for the presence of DNA by
polymerase chain reaction/nested PCR. Recent/active infection (detection of IgM and/or IgG-specific antibodies and presence of viral
DNA) was identified in 47.7% of the 132 individuals with arthropathy. In our study, women were significantly more affected (59.7%)
than men (35.4%) (P = 0.0006). The age group of 11-20 years (84.6%), among female patients, and 21-30 years (42.1%), among
male, were those with the highest incidence rates. The analysis of the temporal distribution of B19-associated arthropaties showed a
cyclic pattern, with peak incidence rates occuring at 3-5 year intervals. Significant diference (P = 0.01) was observed when comparing
both the highest (39.0%) and the lowest (11.0%) seropositivity rates for the years of 1995 and 2000, respectively. The interfalangial
joints of hands and feet were mostly affected, with 50.0% and 48.0% of cases among both women and men, respectively. In a smaller
proportion, other joints such as those of knee, ankle, pulse and shoulder were affected. As for the duration, symptoms lasted 1 to 5
days in 54.0% of the individuals, whereas in 46.0% of them the disease lasted 6-10 days, if considered the subgroup (n = 63) of
patients with recent/active infection by parvovirus B19. In our study, joint clinical manifestations occurred symmetrically. Our results
indicate that B19 may be an important agent of arthropathies in our region, and this underscores the need for specific laboratory
diagnosis when treating patients suffering from acute arthropathy, mainly pregnant women.
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INTRODUCTION
Human parvovirus B19, discovered by COSSART et al.15 , belongs
to the family Parvoviridae, genus Erytrovirus39. The B19 transmission
occurs mainly through respiratory secretions following human-to-human
close contacts4,50. The B19 infection is quite common, affecting children
and adults, often being asymptomatic13,53. The erythema infectiosum (EI)7
is the most common clinical presentation of the B19 infection in children.
In adults, the primary B19 infection has been associated with arthropathy,
transient aplastic crises (TAC) in patients suffering from chronic
haemolytic anemia, and chronic anemia in immunocompromised patients.
Hydrops fetalis may develop as a consequence of infection during the
second trimester of the pregnancy11,16,42,45,52.
Several viral agents have been implicated in the occurrence of the
acute and chronic arthropathies. In the Amazon region, arthropathy is a
common finding in rubella, arboviral diseases (ex.: Oropouche and
Mayaro fevers), Epstein-Barr virus infection and cytomegalovirus
infection1,23,38,51.  Among of the parasitic and bacterial agents, Toxoplasma
gondii and Streptoccocus species may also cause arthropathy19,31.
The pathogenesis of B19 arthropathy needs to be fully elucidated.
Previous studies support the assumption that the joint lesions are
associated with immune complexes40,47. In addition, the tissue joint lysis
caused by parvovirus B19 has been postulated33. The chronic joint lesions
has been associated with persistence of the viral agent in the tissue and
synovial fluid20,34,35.
Several studies conducted in temperate countries2,7,10,24,36,40,44,47 have
reported the joint involvement in association with recent/active B19
infections, with rates ranging from 30.0 to 59.0% among male and female
adult patients, respectively. Furthermore, joint involvement has been
reported in 8.0% children of both sexes. In tropical climate countries,
like Brazil, there have been a few reports associating these viral agent
with cases of arthropathy. Overall, these studies37,38 have shown that
arthropathy is present among individuals with exanthematous illness,
namely E.I, and the positivity rates usually range from 10.0 to 40.0% in
men and women, respectively. It is therefore of our interest to improve
our knowledge on the epidemiology/clinical features of parvovirus B19
infection in our region focussing on its potential for developing
arthropathies.
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MATERIAL AND METHODS
The study was conducted in Belém, Pará between January, 1994
and December, 2000. A total of 220 blood samples were collected from
individuals with arthropathies (arthritis and/or arthralgy) at the Virology
Section of “Instituto Evandro Chagas”. This subgroup of patients (n =
220) was selected from 3,000 individuals with arthropathies who tested
negative for the following agents: measles, rubella, cytomegalovirus,
Epstein-Barr virus, arbovirus (Mayaro, Oropouche and dengue),
Toxoplasma gondii and Streptococcus. Of these, 114 patients were female
and 106 were male, with ages ranging from 2 to 68 years (mean age, 35
years). The blood samples were collected by antecubital venepuncture.
Sera were kept at - 20°C until processing.
The detection of IgM and IgG antibodies to parvovirus B19 was
made using a commercial enzyme-linked immunosorbent assay (ELISA)
developed by DENKA SEIKENTM (Tokyo, Japan). This is an assay that
includes a solid-phase multiple-wells system coated with anti-human
IgM monoclonal antibody, as previously described6,43. Lyophilized,
purified human parvovirus B19 recombinant antigen was used. Sensitivity
and specificity of this assay have been found to be 100% and 97%,
respectively, as based on its comparison with the (gold standard)
radioimmunoassay14. Sera were tested at a (single) dilution of 1:200,
according to the manufacturer. The results of ELISA were calculated
dividing optical density (O.D) values of serum samples by the mean
absorbance of cut-off. The serum samples with IgM antibodies with
absorbance  1.00 were regarded as positive.
A subgroup (n = 132) of individuals with B19 IgM+/IgG+ antibodies
(absorbance,  1.00) and IgM-/IgG+ (O.D of serum samples >5 times the
mean O.D of cut-off) were selected for the B19 DNA detection, using the
polymerase chain reaction (PCR). The PCR technique was performed in
two steps, essentially as reported before18,32. First, amplification was done
using a mixture of external oligonucleotide primers (P1 and P6), followed
by a second amplification (the nested PCR) that involved a mixture of the
internal primers P2 and P5. The B19 recent/active infection was defined as
the presence of IgM+ and/or IgG specific antibodies plus viral DNA detection
in this subgroup (n = 132) of selected individuals. Conventional ELISA and
immunofluorescence indirect assays were used for the detection of both
IgM and IgG antibodies to rubella, measles, Epstein-Barr virus,
cytomegalovirus and Toxoplasma gondii, as previously reported8,12,17,25,29.
Serum specimens were also tested by haemagglutination-inhibition (HI), as
described before46, for the determination of antibodies to Mayaro, Oropouche
and dengue viruses, which are well-know viral agents of exanthematous
illnesses in the Amazon region. The latex assay was used for the detection
of the antiestreptolysin O, for the diagnosis of infection by Streptococcus as
a possible cause of rheumatic fever, as previously described30, in a subgroup
(n = 12) of patients that presented with tonsillar pharyngitis.
The data were analysed using the EPI-INFO software, version 6.0
(Atlanta, GA, USA). Rates were compared by using the Mantel-Haenszel
chi square test of association or Fisher’s exact test, as appropriate.
Significance was defined as P < 0.05.
RESULTS
Nineteen (8.6%) of the 220 patients were IgM and IgG positive (IgM+/
IgG+) to B19 (Table 1). One hundred and sixty nine patients (76.8%)
were identified as being immune, since they were IgM-/IgG+, and 32
(14.6%) of them had neither IgM nor IgG antibodies (IgM-/IgG-). The
results of PCR and nested PCR are shown in the Table 2. The viral DNA
was detected in 17 (12.9%) and 46 (34.8%) of the 132 patients who were
either IgM+/IgG+ (n = 19) and IgM-/IgG+ (n = 113), respectively. The
detection of B19 DNA among female and male patients were 59.7% and
35.4%, respectively (Table 2). Significant difference was observed when
comparing the joint involvement in the subjects of both sexes: P = 0.0006
(a vs b) and P = 0.005 (c vs d) for the age groups 11-20 years and the
subtotal, respectively (Table 2). In the children  10 years of age, B19
DNA positive rates ranged from 50.0 to 75.0%. The age groups 11-20
years (84.6%), among female patients, and 21-30 years (42.1%), among
male, were those with the highest incidence rates. Significant difference
was observed when comparing these two age groups (P = 0.01).
The analysis of the temporal distribution of B19-associated
arthropathies shows a cyclic pattern, with peak incidence rates at 3-5
years intervals. Significant difference (P = 0.01) was observed when
comparing both the highest (39.0%) and the lowest (11.0%) seropositivity
rates, corresponding to 1995 and 2000, respectively (Fig. 1).
The interfalangial joints of hands and feet were mostly affected,
with 50.0% and 48.0% (data not shown in Fig. 2) of cases among both
women and men, respectively. In a smaller proportion of patients, other
Table 1
Detection of antibodies to parvovirus B19 in patients suffering from
arthropathies, Belém, Pará, 1994-2000.
Serological status (%)
Sex/age Total IgM+/IgG+ IgM-/IgG+ IgM-/IgG-
(years) tested
F 19  3 (15.8)  11 (57.9)  5 (26.3)
 10
M 19  0 (0)  14 (73.7)  5 (26.3)
F 28  1 (3.6)  21 (75.0)  6 (21.4)
11-20
M 27  2 (7.4)  19 (70.4)  6 (22.2)
F 26  4 (15.4)  20 (76.9)  2 (7.7)
21-30
M 21  3 (14.3)  17 (80.9)  1 (4.8)
F 20  3 (15.0)  17 (85.0)  0 (0)
31-40
M 19  0 (0)  17 (89.5)  2 (10.5)
F 21  2 (9.5)  17 (81.0)  2 (9.5)
> 40
M 20  1 (5.0)  16 (80.0)  3 (15.0)
F 114  13 (11.4)  86 (75.4)  15 (13.2)
Subtotal
M 106  6 (5.7)  83 (78.3)  17 (16.0)
Total 220  19 (8.6)  169 (76.3)  32 (14.6)
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Table 2
Distribution of recent/active B19 infections associated with arthropathies,
according to sex and age. Belém, Pará, 1994-2000.
Sex/age  Total * IgM+/IgG+ (%) IgM-/IgG+* * (%)
(years) tested  DNA+ DNA- DNA+ DNA-
F  4  3 (75.0) 0 (0) 0 (0) 1 (25.0)
  10
M  8  0 (0) 0 (0) 4 (50.0) 4 (50.0)
F  13  2 (15.4) 0 (0) 9 (69.2)a 2 (15.4)
 11-20
M  15 0 (0) 1 (6.7) 3 (20.0) b 11 (73.3)
F  22  4 (18.2) 0 (0) 6 (27.3) 12 (54.5)
 21-30
M  19  2 (10.5) 1 (5.3) 6 (31.6) 10 (52.6)
F  19  3 (15.8) 0 (0) 8 (42.1) 8 (42.1)
 31 –40
M  12  0 (0) 0 (0) 5 (41.7) 7 (58.3)
F  9  2 (22.2) 0 (0) 3 (33.3) 4 (44.5)
 > 40
M  11  1 ( 9.1) 0 (0) 2 (18.2) 8 (72.7)
F  67  14 (20.9) 0 (0) 26 (38.8) c 27 (40.3)
Subtotal
M  65  3 (4.6) 2 (3.1) 20 (30.8) d 40 (61.5)
Total 132  17 (12.9) 2 (1.5) 46 (34.8) 67 (50.8)
* A total of 88 serum samples not screened by PCR/ nested PCR .
** O.D of specimens, > 5 times that O.D mean of cut off.
a vs b Significant difference between the results (P = 0.0006).
c vs d Significant difference between the results (P = 0.005).
Fig. 1 - Temporal distribution of seropositivity to parvovirus B19 in patients suffering from
arthropathies. Belém, Pará, 1994-2000.
Fig. 2 - Anatomic localization and duration of the arthropathies associated with recent/active B19 infections, according to sex in 63 patients. Belém, Pará, 1994-2000.
joints such as those of knee, ankle, pulse and shoulder were affected. As
for the duration, symptoms lasted 1 to 5 days in 54.0% of the individuals,
whereas in 46.0% of them the disease lasted 6-10 days, if considered the
subgroup (n = 63) of patients with recent/active infection for the
parvovirus B19. In our study, joint involvement occurred symmetrically
(data not shown in Fig. 2).
Negative results were yielded when testing sera for antibodies to a
variety of other pathogens that might be related to arthropathies in our
region, including dengue virus.
DISCUSSION
The analysis of the serologic “status” in the group (n = 220) of
subjects with arthropathies made it possible the selection of a subgroup
(n = 132) of patients who had presented high IgM+/IgG+ and IgM- /
IgG+ antibody levels for B19. Overall, 132 of these serum samples were
examined by PCR/nested PCR techniques, according to previous
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studies10,32. These techniques present greater sensitivity than the ELISA,
mainly in situations that require the diagnosis of recent/active B19
infection leading to joint manifestations9,26. This fact was confirmed by
the results of this investigation, when comparing the number of recent/
active infections detected by ELISA and those detected by nested PCR:
significant difference, as indicated by P = 0.0001. The absence of IgM
antibodies for B19 in sera doesn’t rule out the possibility of recent/active
infection, since these sera may have B19 DNA if it contains high levels
of IgM-/IgG+ antibodies. This condition, observed in our study, has
already been demonstrated by CASSINOTTI et al.9. The sera not
examined (n = 88) by PCR/nested PCR were those showing either no
B19 specific IgG or low levels of B19 specific IgG antibodies detected
by ELISA. In this study, the arthropathies prevailed among female
patients (c vs d, P = 0.005, Table 2), mainly among young women (a vs
b, P = 0.0006). A smaller proportion of male adults were affected, and
cases of polyarthritis and polyarthralgy also involved children < 10 years.
The frequency of joint manifestations associated with parvovirus B19
infection in our investigation was similar to that recorded for adults of
both sexes in temperate countries24, with rates of positivity ranging from
30.0 to 59.0%. However, for the children aged < 10 years our rates were
higher than they were for countries with temperate climate7. The
explanation for this might be related to the rates of B19 primo-infections,
recorded by FREITAS et al.22, among children with ages < 5 years in
Belém, Brazil, in general higher than those for temperate countries5.
The temporal distribution of B19 infection throughout our study
period support the cyclic pattern proposed for the occurrence B19
infections, as recorded by FREITAS et al.21 in Belém, Pará, with peaks
of viral activity at 3-5 year intervals. Of note, the high number of
arthropathies recorded in 1998 were not associated with the B19 and
other bacterial and/or parasitic agents investigated. This fact raises the
possibility that pathogens not investigated in our study be associated
with the disease, as demonstrated in others regions37,41,48,49. Because of
situations like this, 36,38,40 it has been stressed the importance of making
differential diagnosis with arthropathies due to other pathogens, so that
proper therapeutic measure can be taken. In our study, interfalangial
joints of hands and feet were mostly affected. Less often, other joints
such as those of knee, ankle, pulse and shoulder were affected. The
arthropathies associated with the recent/active B19 infection presented
short duration (maximum of 10 days), symmetrical distribution and
disappeared without sequelae. These clinical features have been recorded
in previous studies36,38. In our study, the absence of chronic arthropathies
associated with parvovirus B19, as previously described34,36, could be
explained by the fact that a low number of patients (n = 13) with chronic
joint symptoms (lasting months or years) were enrolled in the present
study. Therefore, arthropathies due to collagen or connective tissue
diseases seemed not having prevailed among our study patients and there
was no evidence that such cases were recent/active B19 infection.
In our study, arthralgy was more frequent than arthritis. The
interfalangial joints (hands and feet) were more related arthralgy, mainly
among women. These results were also reported in other studies36,38. Viruses
other than B19, bacteria or parasitic agents capable to produce acute
arthropathies in our region were ruled out as possible aetiological agents.36,38
In our investigation, the frequent joint manifestations associated with
parvovirus B19, mainly among women, indicate the need for laboratorial
diagnosis of this viral agent, therefore avoiding unproper treatment.
The arthritis/arthralgy in pregnant women may constitute an
important indicator of B19 infection, known to be potentially hazardous
for the concept3,27,28.
 RESUMO
Associação entre parvovírus B19 e artropatias em Belém, Pará,
norte do Brasil
Um total de 220 indivíduos portadores de artropatias foi seleciona-
do em Belém, Pará, entre janeiro de 1994 e dezembro de 2000 e, poste-
riormente, examinado com o propósito de se detectarem anticorpos IgM
e IgG para o parvovírus B19, utilizando-se a técnica imunoenzimática
(ELISA). Um subgrupo (n = 132) de indivíduos com amostras de soro
apresentando altos níveis de anticorpos (IgM+/IgG+ e IgM-/IgG+) foi
usado para detecção de DNA do B19 através da reação em cadeia da
polimerase (PCR) e do “nested” PCR. Infecção recente/ativa (detecção
de IgM e/ou IgG mais a presença de DNA viral) foi diagnosticada em
47,7% dos 132 indivíduos apresentando comprometimento das articula-
ções. O sexo feminino foi mais afetado (59,7%) que o masculino (35,4%),
com diferença estatisticamente significativa (P = 0,0006). Os grupos
etários mais atingidos foram os de 11-20 anos (84,6%), no sexo femini-
no, e 21-30 anos (42,1%), no masculino. A análise da distribuição tem-
poral mostrou um padrão cíclico, com períodos de maior e menor ativi-
dade viral que variam de 3 a 5 anos. Diferença estatisticamente signifi-
cativa (P = 0,01) foi observada quando comparadas as freqüências de
positividade mais alta (39,0%) e mais baixa (11,0%) para os anos de
1995 e 2000, respectivamente. As articulações mais atingidas foram, em
ordem de freqüência, as interfalangianas de mãos e pés, com 50,0% e
48,0% para o sexo feminino e masculino, respectivamente. Em menor
proporção outras articulações tais como as do joelho, tornozelo, pulso e
ombro foram afetadas. Quanto à duração das manifestações articulares,
54,0% evoluíram por 1-5 dias, e 46,0% ao longo de 6-10 dias, conside-
rando o subgrupo (n = 63) de indivíduos com infecção recente/ativa
para o B19 em ambos os sexos. Em nosso estudo, o comprometimento
das articulações apresentou caráter simétrico. Os resultados encontra-
dos demonstraram o freqüente acometimento articular associado às in-
fecções recentes/ativas por parvovírus B19, ressaltando a necessidade
do diagnóstico laboratorial dessa virose, principalmente entre gestantes.
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